Multidisciplinary treatment for patients with stage IV gastric cancer

The role of conversion surgery following chemotherapy 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis

Seung Hoon Beom, Yoon Young Choi, Song Ee Baek, Shuang Xi Li, Joon Seok Lim, Taeil Son, Hyoung Il Kim, Jae Ho Cheong, WooJin Hyung, Seung Ho Choi, Minkyu Jung, Hyo Song Kim, Hei Cheul Jeung, Hyuncheol Chung, SunYoung Rha, Sung Hoon Noh

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: With advances in gastric cancer chemotherapy, conversion surgery has drawn attention as a new strategy to improve the outcome of stage IV disease. We investigated the efficacy of conversion surgery following chemotherapy for patients with stage IV gastric cancer. Methods: We retrospectively reviewed clinico-pathologic variables and oncologic outcomes for 101 patients with stage IV gastric cancer who were treated with systemic chemotherapy followed by gastrectomy with intension of curative resection from January 2005 to December 2012. Results: In terms of the best response from palliative chemotherapy, complete or partial response were observed in 65 patients (64.4%) in overall. Complete response of metastatic site were observed in 72 (71.3%) and 66 (65.3%) patients as best and pre-operative response, respectively. The overall complete macroscopic resection, rate was 56.4%. Eleven patients (10.9%) received combined metastasectomy. There was no postoperative surgery-related mortality for 1 month. The median overall survival time was 26.0 months. Multivariable analysis identified complete macroscopic resection, chemotherapy response (complete response/partial response) of metastatic sites, and change in CEA level as independent prognostic factors contributing to overall survival. Conclusions: Patients with stage IV gastric cancer who exhibit a good clinical response to chemotherapy might obtain greater survival benefit from gastrectomy following chemotherapy compared with patients who exhibit a poor response to chemotherapy. Prospective, randomized trials are required to determine the best strategy for combining initial chemotherapy with subsequent gastrectomy.

Original languageEnglish
Article number1116
JournalBMC cancer
Volume18
Issue number1
DOIs
Publication statusPublished - 2018 Nov 15

Fingerprint

Stomach Neoplasms
Carcinogenesis
Drug Therapy
Health
Gastrectomy
Therapeutics
Survival
Metastasectomy
Mortality

All Science Journal Classification (ASJC) codes

  • Oncology
  • Genetics
  • Cancer Research

Cite this

Beom, Seung Hoon ; Choi, Yoon Young ; Baek, Song Ee ; Li, Shuang Xi ; Lim, Joon Seok ; Son, Taeil ; Kim, Hyoung Il ; Cheong, Jae Ho ; Hyung, WooJin ; Choi, Seung Ho ; Jung, Minkyu ; Kim, Hyo Song ; Jeung, Hei Cheul ; Chung, Hyuncheol ; Rha, SunYoung ; Noh, Sung Hoon. / Multidisciplinary treatment for patients with stage IV gastric cancer : The role of conversion surgery following chemotherapy 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis. In: BMC cancer. 2018 ; Vol. 18, No. 1.
@article{e9c8c9f493d64418ba9c80d588caba3d,
title = "Multidisciplinary treatment for patients with stage IV gastric cancer: The role of conversion surgery following chemotherapy 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis",
abstract = "Background: With advances in gastric cancer chemotherapy, conversion surgery has drawn attention as a new strategy to improve the outcome of stage IV disease. We investigated the efficacy of conversion surgery following chemotherapy for patients with stage IV gastric cancer. Methods: We retrospectively reviewed clinico-pathologic variables and oncologic outcomes for 101 patients with stage IV gastric cancer who were treated with systemic chemotherapy followed by gastrectomy with intension of curative resection from January 2005 to December 2012. Results: In terms of the best response from palliative chemotherapy, complete or partial response were observed in 65 patients (64.4{\%}) in overall. Complete response of metastatic site were observed in 72 (71.3{\%}) and 66 (65.3{\%}) patients as best and pre-operative response, respectively. The overall complete macroscopic resection, rate was 56.4{\%}. Eleven patients (10.9{\%}) received combined metastasectomy. There was no postoperative surgery-related mortality for 1 month. The median overall survival time was 26.0 months. Multivariable analysis identified complete macroscopic resection, chemotherapy response (complete response/partial response) of metastatic sites, and change in CEA level as independent prognostic factors contributing to overall survival. Conclusions: Patients with stage IV gastric cancer who exhibit a good clinical response to chemotherapy might obtain greater survival benefit from gastrectomy following chemotherapy compared with patients who exhibit a poor response to chemotherapy. Prospective, randomized trials are required to determine the best strategy for combining initial chemotherapy with subsequent gastrectomy.",
author = "Beom, {Seung Hoon} and Choi, {Yoon Young} and Baek, {Song Ee} and Li, {Shuang Xi} and Lim, {Joon Seok} and Taeil Son and Kim, {Hyoung Il} and Cheong, {Jae Ho} and WooJin Hyung and Choi, {Seung Ho} and Minkyu Jung and Kim, {Hyo Song} and Jeung, {Hei Cheul} and Hyuncheol Chung and SunYoung Rha and Noh, {Sung Hoon}",
year = "2018",
month = "11",
day = "15",
doi = "10.1186/s12885-018-4998-x",
language = "English",
volume = "18",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

Multidisciplinary treatment for patients with stage IV gastric cancer : The role of conversion surgery following chemotherapy 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis. / Beom, Seung Hoon; Choi, Yoon Young; Baek, Song Ee; Li, Shuang Xi; Lim, Joon Seok; Son, Taeil; Kim, Hyoung Il; Cheong, Jae Ho; Hyung, WooJin; Choi, Seung Ho; Jung, Minkyu; Kim, Hyo Song; Jeung, Hei Cheul; Chung, Hyuncheol; Rha, SunYoung; Noh, Sung Hoon.

In: BMC cancer, Vol. 18, No. 1, 1116, 15.11.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Multidisciplinary treatment for patients with stage IV gastric cancer

T2 - The role of conversion surgery following chemotherapy 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis

AU - Beom, Seung Hoon

AU - Choi, Yoon Young

AU - Baek, Song Ee

AU - Li, Shuang Xi

AU - Lim, Joon Seok

AU - Son, Taeil

AU - Kim, Hyoung Il

AU - Cheong, Jae Ho

AU - Hyung, WooJin

AU - Choi, Seung Ho

AU - Jung, Minkyu

AU - Kim, Hyo Song

AU - Jeung, Hei Cheul

AU - Chung, Hyuncheol

AU - Rha, SunYoung

AU - Noh, Sung Hoon

PY - 2018/11/15

Y1 - 2018/11/15

N2 - Background: With advances in gastric cancer chemotherapy, conversion surgery has drawn attention as a new strategy to improve the outcome of stage IV disease. We investigated the efficacy of conversion surgery following chemotherapy for patients with stage IV gastric cancer. Methods: We retrospectively reviewed clinico-pathologic variables and oncologic outcomes for 101 patients with stage IV gastric cancer who were treated with systemic chemotherapy followed by gastrectomy with intension of curative resection from January 2005 to December 2012. Results: In terms of the best response from palliative chemotherapy, complete or partial response were observed in 65 patients (64.4%) in overall. Complete response of metastatic site were observed in 72 (71.3%) and 66 (65.3%) patients as best and pre-operative response, respectively. The overall complete macroscopic resection, rate was 56.4%. Eleven patients (10.9%) received combined metastasectomy. There was no postoperative surgery-related mortality for 1 month. The median overall survival time was 26.0 months. Multivariable analysis identified complete macroscopic resection, chemotherapy response (complete response/partial response) of metastatic sites, and change in CEA level as independent prognostic factors contributing to overall survival. Conclusions: Patients with stage IV gastric cancer who exhibit a good clinical response to chemotherapy might obtain greater survival benefit from gastrectomy following chemotherapy compared with patients who exhibit a poor response to chemotherapy. Prospective, randomized trials are required to determine the best strategy for combining initial chemotherapy with subsequent gastrectomy.

AB - Background: With advances in gastric cancer chemotherapy, conversion surgery has drawn attention as a new strategy to improve the outcome of stage IV disease. We investigated the efficacy of conversion surgery following chemotherapy for patients with stage IV gastric cancer. Methods: We retrospectively reviewed clinico-pathologic variables and oncologic outcomes for 101 patients with stage IV gastric cancer who were treated with systemic chemotherapy followed by gastrectomy with intension of curative resection from January 2005 to December 2012. Results: In terms of the best response from palliative chemotherapy, complete or partial response were observed in 65 patients (64.4%) in overall. Complete response of metastatic site were observed in 72 (71.3%) and 66 (65.3%) patients as best and pre-operative response, respectively. The overall complete macroscopic resection, rate was 56.4%. Eleven patients (10.9%) received combined metastasectomy. There was no postoperative surgery-related mortality for 1 month. The median overall survival time was 26.0 months. Multivariable analysis identified complete macroscopic resection, chemotherapy response (complete response/partial response) of metastatic sites, and change in CEA level as independent prognostic factors contributing to overall survival. Conclusions: Patients with stage IV gastric cancer who exhibit a good clinical response to chemotherapy might obtain greater survival benefit from gastrectomy following chemotherapy compared with patients who exhibit a poor response to chemotherapy. Prospective, randomized trials are required to determine the best strategy for combining initial chemotherapy with subsequent gastrectomy.

UR - http://www.scopus.com/inward/record.url?scp=85056618668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056618668&partnerID=8YFLogxK

U2 - 10.1186/s12885-018-4998-x

DO - 10.1186/s12885-018-4998-x

M3 - Article

VL - 18

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 1116

ER -